MSFT 409.6999 -1.5286% AAPL 222.71 -1.8034% NVDA 128.3057 2.7103% GOOGL 163.14 -2.3465% GOOG 164.6592 -2.3142% AMZN 180.47 -3.2384% META 585.16 -1.8089% AVGO 175.79 -0.4812% TSLA 241.6955 -3.3527% TSM 183.57 1.3303% LLY 899.35 1.374% V 273.29 -1.6695% JPM 209.74 -0.7007% UNH 584.575 -1.1206% NVO 117.48 2.05% WMT 79.45 -1.8409% LVMUY 148.82 1.4451% XOM 125.47 0.5127% LVMHF 745.0 1.5609% MA 491.24 -1.298%
Last update at 2024-10-07T18:47:00Z
Is There Now An Opportunity In USANA Health Sciences, Inc. (NYSE:USNA)?
Wed 02 Oct 24, 01:33 PMUSANA Executive Chairman Kevin Guest Celebrates Country Music Month, Mental Balance
Tue 01 Oct 24, 11:55 AMUSANA Ranked #1 Brand of Co-enzyme Q10 Sold Directly in Australia
Tue 17 Sep 24, 11:07 PMQ2 Earnings Roundup: BeautyHealth (NASDAQ:SKIN) And The Rest Of The Personal Care Segment
Tue 17 Sep 24, 08:13 AMPersonal Care Stocks Q2 Teardown: Estée Lauder (NYSE:EL) Vs The Rest
Thu 05 Sep 24, 08:56 AMUSANA Executive Chairman Kevin Guest Celebrates Entrepreneurs in Today's Business World
Tue 03 Sep 24, 11:47 AMSome Investors May Be Worried About USANA Health Sciences' (NYSE:USNA) Returns On Capital
Sun 01 Sep 24, 02:25 PMReflecting On Personal Care Stocks’ Q2 Earnings: USANA (NYSE:USNA)
Mon 12 Aug 24, 07:50 AMUSANA Health Sciences Second Quarter 2024 Earnings: Misses Expectations
Fri 09 Aug 24, 10:16 AMReflecting On Personal Care Stocks’ Q1 Earnings: Nu Skin (NYSE:NUS)
Fri 26 Jul 24, 08:05 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 108.62M | 170.64M | 177.95M | 150.50M | 191.51M |
| Minority interest | - | - | - | - | - |
| Net income | 69.35M | 116.50M | 124.66M | 100.53M | 126.22M |
| Selling general administrative | 262.30M | 279.11M | 261.19M | 267.73M | 275.06M |
| Selling and marketing expenses | 434.79M | 519.27M | 487.86M | 459.48M | 525.13M |
| Gross profit | 804.71M | 968.57M | 925.53M | 873.40M | 988.54M |
| Reconciled depreciation | 21.41M | 22.19M | 22.51M | 23.01M | 16.84M |
| Ebit | 86.20M | 148.00M | 153.98M | 123.18M | 171.51M |
| Ebitda | 107.61M | 170.19M | 176.49M | 146.19M | 188.35M |
| Depreciation and amortization | 21.41M | 22.19M | 22.51M | 23.01M | 16.84M |
| Non operating income net other | - | 0.51M | 1.96M | 4.37M | 3.19M |
| Operating income | 107.61M | 170.19M | 176.49M | 146.19M | 188.35M |
| Other operating expenses | 890.99M | 1016.27M | 958.15M | 914.71M | 1000.89M |
| Interest expense | 0.19M | 0.06M | 0.51M | 0.07M | 0.04M |
| Tax provision | 39.27M | 54.14M | 53.28M | 49.97M | 65.29M |
| Interest income | 3.79M | 2.52M | 2.54M | 4.71M | 4.43M |
| Net interest income | 3.60M | 2.46M | 2.03M | 4.64M | 4.39M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 39.27M | 54.14M | 53.28M | 49.97M | 65.29M |
| Total revenue | 998.60M | 1186.46M | 1134.64M | 1060.90M | 1189.25M |
| Total operating expenses | 697.10M | 798.37M | 749.04M | 727.21M | 800.18M |
| Cost of revenue | 193.89M | 217.90M | 209.11M | 187.50M | 200.71M |
| Total other income expense net | 1.01M | 0.45M | 1.46M | 4.31M | 3.16M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 69.35M | 116.50M | 124.66M | 100.53M | 126.22M |
| Net income applicable to common shares | 69.35M | 116.50M | 124.66M | 100.53M | 126.22M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 596.55M | 577.74M | 640.89M | 516.93M | 554.46M |
| Intangible assets | 32.43M | 30.44M | 30.80M | 29.84M | 31.81M |
| Earning assets | - | - | - | - | - |
| Other current assets | 28.87M | 26.97M | 23.14M | 25.54M | 32.52M |
| Total liab | 162.08M | 182.62M | 199.24M | 165.22M | 163.32M |
| Total stockholder equity | 434.47M | 395.12M | 441.65M | 351.71M | 391.15M |
| Deferred long term liab | - | 7.50M | 12.01M | 10.28M | 13.37M |
| Other current liab | 105.02M | 120.57M | 125.31M | 101.40M | 102.92M |
| Common stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Capital stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Retained earnings | 391.64M | 344.64M | 382.79M | 306.15M | 329.50M |
| Other liab | 10.56M | 21.83M | 12.01M | 11.85M | 14.63M |
| Good will | 17.37M | 17.67M | 17.37M | 16.64M | 16.82M |
| Other assets | 50.68M | 62.73M | 66.99M | 26.17M | 23.92M |
| Cash | 288.42M | 239.83M | 311.92M | 234.83M | 214.33M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 143.83M | 160.79M | 168.07M | 136.10M | 148.69M |
| Current deferred revenue | 20.88M | 19.64M | 15.95M | 13.85M | 15.05M |
| Net debt | -281.52800M | -232.75200M | -303.30100M | -226.50700M | -214.32600M |
| Short term debt | 6.89M | 7.08M | 8.62M | 8.32M | 20.77M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 6.89M | 7.08M | 8.62M | 8.32M | - |
| Other stockholder equity | 55.60M | 50.01M | 62.46M | 59.45M | 72.01M |
| Property plant equipment | 111.69M | 101.78M | 100.44M | 95.23M | 92.03M |
| Total current assets | 384.38M | 365.12M | 425.29M | 329.28M | 392.33M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 384.67M | 347.01M | 441.65M | 305.24M | 342.52M |
| Short term investments | - | - | - | 0.00000M | 63.54M |
| Net receivables | 7.21M | 7.16M | 7.42M | 8.76M | 14.03M |
| Long term debt | - | - | - | - | - |
| Inventory | 67.09M | 98.32M | 90.22M | 68.91M | 81.95M |
| Accounts payable | 11.05M | 13.51M | 18.20M | 12.53M | 9.95M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -12.78700M | 0.46M | -3.62500M | -13.90100M | -10.38700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.02M | 0.02M | 0.02M | 0.02M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 344.64M | 382.79M | 306.15M | 329.50M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 54.80M | 57.89M | 62.35M | 42.86M | 18.13M |
| Deferred long term asset charges | - | - | - | - | 3.35M |
| Non current assets total | 212.17M | 212.62M | 215.60M | 187.66M | 162.13M |
| Capital lease obligations | 6.89M | 7.08M | 8.62M | 8.32M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -12.37000M | -1.43900M | -18.87300M | 64.05M | -57.95100M |
| Change to liabilities | -2.65600M | -16.02800M | 22.53M | -28.96900M | 16.98M |
| Total cashflows from investing activities | -12.37000M | -14.18700M | -33.96100M | 47.49M | -69.00300M |
| Net borrowings | - | - | -0.04600M | -0.06500M | - |
| Total cash from financing activities | -30.08800M | -181.41200M | -59.44200M | -152.05200M | -105.27700M |
| Change to operating activities | -12.37000M | -13.78700M | 11.26M | -23.61500M | 17.07M |
| Net income | 69.35M | 116.50M | 124.66M | 100.53M | 126.22M |
| Change in cash | 47.67M | -72.28400M | 78.25M | 20.45M | -33.30100M |
| Begin period cash flow | 243.65M | 315.94M | 237.69M | 217.23M | 250.53M |
| End period cash flow | 291.32M | 243.65M | 315.94M | 237.69M | 217.23M |
| Total cash from operating activities | 103.90M | 121.23M | 160.40M | 126.73M | 152.12M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 21.41M | 22.19M | 22.51M | 23.01M | 16.84M |
| Other cashflows from investing activities | 4.55M | 0.01M | 0.00600M | 0.02M | 0.38M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 21.88M | -10.50100M | -16.78400M | 12.99M | -23.10100M |
| Change to account receivables | - | - | 0.28M | 0.23M | -0.65800M |
| Sale purchase of stock | -25.38200M | -177.83700M | -57.02900M | -150.00000M | -105.37500M |
| Other cashflows from financing activities | 6.29M | -3.57500M | 57.59M | 2.95M | 0.10M |
| Change to netincome | 6.29M | 11.39M | 12.67M | 11.99M | 17.46M |
| Capital expenditures | 10.40M | 12.76M | 15.09M | 16.57M | 11.43M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | 6.83M | 3.57M | 15.45M | -2.28400M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -74.37200M | 67.00M | 22.18M | -22.16100M |
| Change in working capital | 6.85M | -28.86000M | 0.56M | -8.79000M | -7.74900M |
| Stock based compensation | 13.33M | 14.30M | 14.39M | 15.54M | 14.96M |
| Other non cash items | 0.14M | 0.06M | 0.70M | 0.08M | 1.15M |
| Free cash flow | 93.50M | 108.46M | 145.31M | 110.16M | 140.69M |
Sector: Consumer Defensive Industry: Packaged Foods
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| USNA USANA Health Sciences Inc |
-0.635 1.77% | 35.30 | 17.11 | 16.89 | 1.07 | 2.11 | 0.76 | 5.94 |
| NSRGF Nestle SA |
-0.02 0.02% | 98.23 | 26.86 | 18.76 | 3.13 | 7.10 | 3.81 | 21.70 |
| NSRGY Nestle SA ADR |
-0.58 0.59% | 97.52 | 26.82 | 18.66 | 3.18 | 7.07 | 3.81 | 21.70 |
| KHC Kraft Heinz Co |
-0.03 0.09% | 34.56 | 15.59 | 11.79 | 1.64 | 0.88 | 2.34 | 11.32 |
| DANOY Danone PK |
0.06 0.43% | 14.17 | 28.42 | 16.39 | 1.44 | 2.23 | 1.85 | 12.41 |
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
3838 West Parkway Boulevard, Salt Lake City, UT, United States, 84120
| Name | Title | Year Born |
|---|---|---|
| Mr. Kevin G. Guest | Chairman & CEO | 1963 |
| Mr. Jim Brown | Pres | 1969 |
| Mr. G. Douglas Hekking | Chief Financial Officer | 1970 |
| Mr. Walter Noot | Chief Operating Officer | 1966 |
| Mr. David Mulham | Chief Sales Officer | 1960 |
| Dr. Myron W. Wentz | Founder & Chairman Emeritus | 1941 |
| Dr. John Cuomo | Exec. Director of Product Devel. & Technology | NA |
| Dr. Robert A. Sinnott | Chief Scientific Officer | 1965 |
| Mr. Patrique Richards | Exec. Director of Investor Relations & Bus. Devel. | NA |
| Mr. P. Joshua Foukas | Chief Legal Officer, Gen. Counsel & Corp. Sec. | 1976 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...